Drugs / Patritumab
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02350712 | Dec 2014 → Mar 2016 | head and neck squamous cell carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT01957280 | Jun → Oct 2013 | cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT01479023 | Apr 2012 → Jan 2013 | carcinoma, lymphoma, sarcoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT00730470 | Aug 2008 → Jul 2010 | cancer | U3 Pharma GmbH | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01512199 | Nov 2011 → Jan 2015 | breast cancer | Daiichi Sankyo | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT01211483 | Sep 2010 → Oct 2013 | non-small cell lung carcinoma | Daiichi Sankyo | Completed | Mixed |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02633800 | Dec 2015 → Jan 2018 | head and neck neoplasm | Daiichi Sankyo | Terminated | Missed primary |
| Phase 2 | NCT01042379 | Mar 2010 → Dec 2030 expected | HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02134015 | Mar 2014 → Nov 2016 | non-small cell lung carcinoma | Daiichi Sankyo | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-05-31 | Daiichi Sankyo | Results Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer (NSCLC) daiichisankyo.com ↗
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the two-part phase 3 HER3-Lung study of patritumab will not proceed into the second part. |
All press releases naming this drug 8 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | patritumab | “The purpose of this study was to evaluate the safety, dosimetry, and apparent receptor occupancy (RO) of [(64)Cu]DOTA-patritumab, a radiolabeled monoclonal antibody directed...” PMID 26567113 ↗ Jun 2016 |
| Known as | AMG 888 | “Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic...” NCT01512199 ↗ |
| Known as | U3-1287 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01512199 ↗ |
| Action | Inhibit | “patritumab blocks HER3 activation” PMID 31648099 ↗ Oct 2019 |
| Modality | Monoclonal antibody | “fully human monoclonal antibody” NCT00730470 ↗ |
| Route | Intravenous | “IV Infusion” NCT00730470 ↗ |
| Target | ERBB3 | “a radiolabeled monoclonal antibody directed against HER3/ERBB3” PMID 26567113 ↗ Jun 2016 |